SCHEMBL6346010

SCHEMBL6346010

COC(=O)c1ccccc1NC(=O)c1ccc(Oc2ccc3cc(O[C@H]4CC[C@@H](N(Cc5ccccc5)Cc5ccccc5)CC4)ccc3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.49
MAPT P10636 5/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
ELANE P08246 1/20 0.43
PRTN3 P24158 1/20 0.43
TSHR P16473 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 2/20 0.43
HSD17B10 Q99714 1/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346008 1.00 PDE5A (0.49) PDE5AMAPTKDM4EALDH1A1HPGD
SCHEMBL6348792 0.94 PDE5A (0.51) PDE5AMAPTKDM4EALDH1A1HPGD
SCHEMBL6348793 0.94 PDE5A (0.51) PDE5AMAPTKDM4EALDH1A1HPGD
SCHEMBL6339790 0.89 KDM4E (0.42) PDE5AKDM4EALDH1A1TSHRPOLB
SCHEMBL6339792 0.89 KDM4E (0.42) PDE5AKDM4EALDH1A1TSHRPOLB
SCHEMBL6346432 0.88 TACR1 (0.42) PDE5AKDM4EALDH1A1TSHRPOLB
SCHEMBL6346430 0.88 TACR1 (0.42) PDE5AKDM4EALDH1A1TSHRPOLB
SCHEMBL6337450 0.84 PDE5A (0.53) PDE5AMAPTKDM4EALDH1A1HPGD
SCHEMBL6337451 0.84 PDE5A (0.53) PDE5AMAPTKDM4EALDH1A1HPGD
SCHEMBL6337042 0.83 KDM4E (0.45) KDM4EALDH1A1TSHRPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 PDE5A 3910/4885MAPT 2538/4885KDM4E 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.